Lilly Inks Deal With BioMS For Phase III Multiple Sclerosis Compound

Collaboration valued at $497 million plus royalties aims to develop, commercialize synthetic peptide MBP8298, Lilly tells “The Pink Sheet” DAILY.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet